Research programme: anticancer therapeutics - SignalRx Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - SignalRx Pharmaceuticals

Alternative Names: Delta-PI3K/BRD4 inhibitor - SignalRx; Dual PI3K inhibitors - SignalRx; Pan-PI3K/BRD4 inhibitor - SignalRx; PI3K/BRAF dual inhibitor - SignalRx; PI3K/CDK4-6/BRD4 inhibitor programme; PI3K/CDK4-6/BRD4 inhibitors - SignalRx; PI3K/HDAC dual inhibitor - SignalRx; PI3K/MEK dual inhibitor - SignalRx; PI3K/OTHER dual inhibitor - SignalRx; PI3K/PARP dual inhibitor - SignalRx; SF 2506; SF 2523; SF 2535; SF 2558HA; SF 2626; SF 5000; SRX 2523; SRX 2558; SRX 2626; SRX 3636; SRX 5000

Latest Information Update: 10 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Indiana University School of Medicine
  • Developer SignalRx Pharmaceuticals
  • Class Pyrones; Small molecules; Thiophenes
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4-protein-inhibitors; Cyclin-dependent kinase inhibitors; DNA cytosine 5 methyltransferase inhibitors; Histone deacetylase inhibitors; Isocitrate dehydrogenase 1 inhibitors; Mitogen-activated protein kinase kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto oncogene protein b raf inhibitors; Ras signal transduction pathway inhibitors; Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Apr 2017 SignalRx Pharmaceuticals' triple PI3K/CDK4-6/BRD4 inhibitor and PI3K-BRD4 programmes are available for licensing (http://www.signalrx.com/signal-rx/partners/)
  • 03 Apr 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer released by SignalRx Pharmaceuticals
  • 31 Jan 2017 Preclinical data of SF 2523 in Cancer released by SignalRx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top